Related references
Note: Only part of the references are listed.Metformin therapy in patients with chronic kidney disease
J. K. Duong et al.
DIABETES OBESITY & METABOLISM (2012)
Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus
Christophe Bardin et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Establishment of a Database of Metformin Plasma Concentrations and Erythrocyte Levels in Normal and Emergency Situations
Jean-Daniel Lalau et al.
CLINICAL DRUG INVESTIGATION (2011)
Clinical Pharmacokinetics of Metformin
Garry G. Graham et al.
CLINICAL PHARMACOKINETICS (2011)
Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease?
Helen J. Nye et al.
NEPHRON CLINICAL PRACTICE (2011)
The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c
Mette M. H. Christensen et al.
PHARMACOGENETICS AND GENOMICS (2011)
Novel Assay of Metformin Levels in Patients With Type 2 Diabetes and Varying Levels of Renal Function Clinical recommendations
Anders Frid et al.
DIABETES CARE (2010)
The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin
M. V. Tzvetkov et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Expression of Organic Cation Transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) Is Affected by Genetic Factors and Cholestasis in Human Liver
Anne T. Nies et al.
HEPATOLOGY (2009)
Lean body mass normalizes the effect of obesity on renal function
Sarayut Janmahasatian et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection
Juliana F. Roos et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus
Ying Hong et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation
Masayo Aoki et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics
Y. Shu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Conditional weighted residuals (CWRES): A model diagnostic for the FOCE method
Andrew C. Hooker et al.
PHARMACEUTICAL RESEARCH (2007)
Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine
Mingyan Zhou et al.
DRUG METABOLISM AND DISPOSITION (2007)
Derivation of various NONMEM estimation methods
Yaning Wang
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide
Karl Brendel et al.
PHARMACEUTICAL RESEARCH (2006)
A note on exact tests of Hardy-Weinberg equilibrium
JE Wigginton et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2005)
Steady-state pharmacokinetics of a novel extended-release metformin formulation
P Timmins et al.
CLINICAL PHARMACOKINETICS (2005)
Quantification of lean bodyweight
S Janmahasatian et al.
CLINICAL PHARMACOKINETICS (2005)
The bootstrap: A technique for data-driven statistics. Using computer-intensive analyses to explore experimental data
AR Henderson
CLINICA CHIMICA ACTA (2005)
Measurement of metformin concentration in erythrocytes: clinical implications
JD Lalau et al.
DIABETES OBESITY & METABOLISM (2003)
Rapid determination of metformin in human plasma using ion-pair HPLC
A Zarghi et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2003)
Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease
M Cullberg et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Mechanism by which metformin reduces glucose production in type 2 diabetes
RS Hundal et al.
DIABETES (2000)